10 May 2022
\n \n \n \nThis research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.
\n \n\n \n \n9 May 2022
\n \n \n \nNucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.
\n \n\n \n \n4 May 2022
\n \n \n \nThe shares are expected to begin trading on the Nasdaq Global Select Market on 6 May 2022 under the symbol \u201cPEPG.\u201d The offering is expected to close on 10 May 2022, subject to the satisfaction of customary closing conditions.
\n \n\n \n \n10 April 2022
\n \n \n \nThe company plans to develop Lilly\u2019s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.
\n \n\n \n \n5 April 2022
\n \n \n \nInitiation of Phase 1 Study marks PepGen\u2019s transition to a clinical-stage company. This Phase 1 Healthy Normal Volunteer (HNV) study will evaluate safety and tolerability as the primary objective. It will begin to evaluate the delivery and target engagement of PGN-EDO51 to enable subsequent patient trials.
\n \n\n \n \n25 January 2022
\n \n \n \nThe research collaboration will investigate TPOXX\u00ae (tecovirimat) in combination with Bioarchitech\u2019s proprietary vaccinia-based immunotherapy platform in preclinical studies.
\n \n\n \n \n3 January 2022
\n \n \n \nKyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.
\n \n\n \n \n14 December 2021
\n \n \n \nThe two companies share the same goals, to improve the lives of those dealing with liver disease.
\n \n\n \n \n22 November 2021
\n \n \n \nHelping people get the answers they need to make more informed decisions across the cancer continuum.
\n \n\n \n \n15 November 2021
\n \n \n \nCyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.
\n \n\n \n \n5 November 2021
\n \n \n \nThe technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome\u2019s platform in the discovery of genetic targets for innovative precision medicine development.
\n \n\n \n \n1 November 2021
\n \n \n \nKyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.
\n \n\n \n \n21 October 2021
\n \n \n \nRecipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.
\n \n\n \n \n4 August 2021
\n \n \n \nProceeds to support expansion and advancement of PepGen\u2019s pipeline of Enhanced Delivery Oligonucleotide (EDO) therapies for neuromuscular and neurologic diseases.
\n \n\n \n \n22 July 2021
\n \n \n \nAfter a highly successful start, Theolytics is ready for the next step in its journey and is moving to The Oxford Science Park. The company will be the first tenant moving into the newly refurbished Sherard Building.
\n \n\n \n \n24 June 2021
\n \n \n \nMediMabBio has started global clinical trials of its flagship pipeline. After securing R&D funding through a Series A round earlier this year, it will collaborate with a UK clinical trial institution to conduct joint research to develop a treatment for liver cancer.
\n \n\n \n \n17 June 2021
\n \n \n \nThe funding will be used to advance the development of Ochre Bio\u2019s RNA therapies and expand its deep phenotyping platform to identify and validate new liver targets.
\n \n\n \n \n13 June 2021
\n \n \n \nOXvax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for treating solid tumour cancers.
\n \n\n \n \n10 June 2021
\n \n \n \nAlchemab Therapeutics, a former resident company at Oxford's BioEscalator, has won Best Start-up Biotech Company at the prestigious 2020 OBN Awards, presented on Friday 11 June at the Royal Lancaster in London.
\n \n\n \n \n31 May 2021
\n \n \n \nMoA Technology is in the process of moving to the Bellhouse Building at the Oxford Science Park to continue its mission to provide farmers with a diverse choice of innovative technologies for weed control.
\n \n\n \n \n